NEOT Neothetics Inc.

0.40
+0.03  (9%)
Previous Close 0.36
Open 0.36
Price To book 0.84
Market Cap 5463540
Shares 13,831,747
Volume 516,003
Short Ratio 1.66
Av. Daily Volume 790,669

SEC filingsSee all SEC filings

  1. 8-K - Current report 171019780
  2. 8-K - Current report 171019774
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 171019758
  4. 8-K/A [Amend] - Current report 17960763
  5. 8-K - Current report 17958654

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 endpoints not met December 2015. Phase 2 trial initiated December 23, 2016 with data released June 26, 2017 - no efficacy shown.
LIPO-202
Reduction of localized fat deposits under the chin (submental fat)
Phase 2 trial planned pending data from submental trial.
LIPO-202
Reduction of central abdominal bulging

SEC Filings

  1. 8-K - Current report 171019780
  2. 8-K - Current report 171019774
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 171019758
  4. 8-K/A [Amend] - Current report 17960763
  5. 8-K - Current report 17958654
  6. 8-K - Current report 17931109
  7. 8-K - Current report 17922018
  8. 10-Q - Quarterly report [Sections 13 or 15(d)] 17832605
  9. 8-K - Current report 17832559
  10. DEF 14A - Other definitive proxy statements 17791718